Fennec Pharmaceuticals’ (FENC) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Fennec Pharmaceuticals (NASDAQ:FENC) in a report published on Monday, Stock Target Advisor reports. They currently have a $17.00 price objective on the stock.

Other analysts also recently issued research reports about the stock. ValuEngine downgraded shares of Fennec Pharmaceuticals from a buy rating to a hold rating in a report on Friday, November 29th. Zacks Investment Research upgraded shares of Fennec Pharmaceuticals from a hold rating to a buy rating and set a $5.75 target price on the stock in a research report on Friday, November 15th.

FENC stock opened at $6.27 on Monday. Fennec Pharmaceuticals has a fifty-two week low of $3.26 and a fifty-two week high of $7.65. The stock has a market capitalization of $119.97 million, a price-to-earnings ratio of -12.55 and a beta of 0.21. The business’s fifty day moving average price is $5.33 and its two-hundred day moving average price is $4.52.

Fennec Pharmaceuticals (NASDAQ:FENC) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.11. Equities research analysts expect that Fennec Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Wedbush Securities Inc. bought a new position in Fennec Pharmaceuticals during the 3rd quarter worth $57,000. Atria Investments LLC acquired a new stake in shares of Fennec Pharmaceuticals during the 2nd quarter worth $215,000. Hartford Financial Management Inc. grew its holdings in shares of Fennec Pharmaceuticals by 65.0% during the 2nd quarter. Hartford Financial Management Inc. now owns 20,300 shares of the company’s stock worth $81,000 after purchasing an additional 8,000 shares in the last quarter. Paloma Partners Management Co bought a new position in shares of Fennec Pharmaceuticals in the second quarter worth $218,000. Finally, United Services Automobile Association increased its position in shares of Fennec Pharmaceuticals by 32.1% in the second quarter. United Services Automobile Association now owns 229,983 shares of the company’s stock worth $920,000 after purchasing an additional 55,933 shares during the period. Hedge funds and other institutional investors own 42.57% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

See Also: What is a Lock-Up Period?

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.